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Schizophrenia is associated with extensive neurocognitive and behavioral impairments. Studies indicate that N-acetylaspartate (NAA), a
marker of neuronal integrity, and choline, a marker of cell membrane turnover and white matter integrity, may be altered in
schizophrenia. Davunetide is a neurotrophic peptide that can enhance cognitive function in animal models of neurodegeneration.
Davunetide has recently demonstrated modest functional improvement in a study of people with schizophrenia. In a subset of these
subjects, proton magnetic resonance spectroscopy (1H-MRS) was conducted to explore the effects of davunetide on change in NAA/
creatine (NAA/Cr) and choline/creatine (choline/Cr) over 12 weeks of treatment. Of 63 outpatients with schizophrenia who received
randomized davunetide (5 and 30 mg/day) or placebo in the parent clinical trial, 18 successfully completed 1H-MRS in dorsolateral
prefrontal cortex (DLPFC) at baseline and at 12 weeks. Cognition was assessed using the MATRICS Consensus Cognitive Battery
(MCCB). NAA/Cr was unchanged for combined high- and low-dose davunetide groups (N¼ 11). NAA/Cr in the high-dose davunetide
group (N¼ 8) suggested a trend increase of 8.0% (P¼ 0.072) over placebo (N¼ 7). Choline/Cr for combined high- and low-dose
davunetide groups suggested a 6.4% increase (P¼ 0.069), while the high-dose group showed a 7.9% increase (P¼ 0.040) over placebo.
Baseline NAA/Cr correlated with the composite MCCB score (R¼ 0.52, P¼ 0.033), as did individual cognitive domains of attention/
vigilance, verbal learning, and social cognition; however, neither metabolite correlated with functional capacity. In this exploratory study,
12 weeks of adjunctive davunetide appeared to produce modest increases in NAA/Cr and choline/Cr in DLPFC in people with
schizophrenia. This is consistent with a potential neuroprotective mechanism for davunetide. The data also support use of MRS as a
useful biomarker of baseline cognitive function in schizophrenia. Future clinical and preclinical studies are needed to fully define the
mechanism of action and cognitive effects of davunetide in schizophrenia.
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Cognitive impairment represents a core deficit in patients
with schizophrenia. Neuroanatomical findings have emer-
ged that may contribute to this deficit. For example,
structural magnetic resonance imaging (MRI) studies have
demonstrated reduced gray matter volume across several
cortical regions subserving cognitive functions that are
impaired in schizophrenia (Wright et al, 2000). Further-
more, longitudinal structural MRI studies indicate that
cortical gray matter loss may be progressive, especially in
the early stages of psychosis (Gur et al, 1998; Thompson
et al, 2001; Van Haren et al, 2008). Consistent with MRI
gray matter volume loss, postmortem studies have found
reduced cortical neuropil (Rajkowska et al, 1998; Selemon
et al, 1995, 1998), reduced dendritic length (Glantz and
Lewis, 1997) and reduced dendritic spine density (Black
et al, 2004; Garey et al, 1998; Glantz and Lewis, 2000).
Increasingly, white matter neuropathology has also been
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implicated in schizophrenia including reduced glial cell
density and reduced myelin-related mRNA expression in
several cortical regions (Walterfang et al, 2011), as well as
diffusion tensor imaging studies showing altered fractional
anisotropy, including in fronto-temporal white matter tracts
(Shenton et al, 2010). Taken together, these data provide a
rationale for testing the potential cognitive benefits of
compounds with neurotrophic properties.
Davunetide is an eight-amino acid peptide representing
the biologically active derivative of activity-dependent
neuroprotective protein (ADNP). Davunetide demonstrates
neuroprotective and neurotrophic activity in several animal
models of neurodegeneration (Gozes, 2011). Davunetide has
demonstrated cognitive enhancement in a Phase II study in
people with mild cognitive impairment and is currently
being studied for progressive supranuclear palsy (Gold et al,
2012). To examine its pro-cognitive potential in schizo-
phrenia, a randomized, placebo-controlled study of davu-
netide was conducted in 63 people with schizophrenia
taking stable doses of antipsychotics. Although the
MATRICS Consensus Cognitive Battery (MCCB) composite
score did not change with treatment, the UCSD
Performance-based Skills Assessment (UPSA) composite
score—the functional co-primary outcome measure—
demonstrated a significant improvement for davunetide
over placebo (Javitt et al, 2012).
To provide in vivo insight into the mechanism of action
of davunetide in schizophrenia, proton magnetic resonance
spectroscopy (1H-MRS) was performed on a subset of
subjects in this study. N-acetylaspartate (NAA), a neuron-
specific brain metabolite synthesized from aspartic acid and
acetyl-coenzyme A, is the most abundant signal in brain
1H-MRS spectra. Although the biological function of NAA
remains uncertain, NAA normalized to creatine (Cr) is
considered a useful measure of neuronal integrity in various
neuropathological conditions (Moffett et al, 2007). For
example, NAA/creatine (NAA/Cr) is consistently reduced in
classic neurodegenerative disorders such as Alzheimer’s
disease (Soher et al, 2005) and multiple sclerosis (Sajja et al,
2009). Reduced NAA/Cr can also occur in settings of
neuronal atrophy without neuronal loss, such as in a simian
model of HIV dementia, in which NAA/Cr was reduced in
parallel with synaptophysin, a well-established synaptic
marker protein (Lentz et al, 2005). MRS has also been
applied to schizophrenia, and many studies have demon-
strated 5–10% reductions in NAA/Cr in frontal cortex and
hippocampus, confirmed by meta-analysis (Brugger et al,
2011; Steen et al, 2005). Cross-sectional studies have
demonstrated a correlation between cognitive deficits and
reduced NAA/Cr in schizophrenia (Bertolino et al, 2003;
Callicott et al, 2000), suggesting that NAA/Cr may represent
a useful biomarker to assess longitudinal change in studies
of cognitive enhancing treatments in this patient group.
Choline represents another abundant signal in 1H-MRS
spectra. Choline is a primary constituent of cell membranes,
especially myelin, and is often considered a marker of cell
membrane turnover and white matter integrity (Sajja et al,
2009). Brain choline levels by 1H-MRS have been reported
in patients with schizophrenia and although several studies
reported elevated choline levels in caudate nucleus com-
pared with controls (Bustillo et al, 2002; Fujimoto et al,
1996), a meta-analysis found no differences in choline levels
in frontal cortex between patient and control subjects (Steen
et al, 2005).
The current study used 1H-MRS to measure the effects of
davunetide compared with placebo on change in NAA/Cr
and choline/creatine (choline/Cr) over 12 weeks in dorso-
lateral prefrontal cortex (DLPFC) in people with schizo-
phrenia. It was hypothesized that davunetide would
increase NAA/Cr and choline/Cr.
MATERIALS AND METHODS
Setting and Subjects
The parent study was conducted at seven academic medical
centers as part of the National Institute of Mental Health-
funded Treatment Units for Research on Neurocognition in
Schizophrenia (TURNS) consortium. The parent study was
a 12-week, double-blind, parallel group, randomized clinical
trial to evaluate the cognitive effects of intranasal davune-
tide at two doses (5 and 30 mg) or placebo in people with
schizophrenia (Javitt et al, 2012). Only subjects who were
enrolled in the parent protocol were eligible to participate in
the MRS protocol. Subjects were enrolled in the MRS
protocol at four TURNS sites (Columbia University,
Washington University, Duke University, Harvard Univer-
sity). The study was approved by the local Institutional
Review Board at each of the participating sites. Of the 63
subjects in the parent clinical trial, 31 provided informed
consent to participate in the MRS protocol. 19 completed
both baseline and end-of-study scans.
Inclusion criteria: people aged 18–60 years with a
diagnosis of schizophrenia (DSM-IV criteria) who demon-
strated clinical stability and were receiving stable doses
of one or more second generation antipsychotics and/or a
long-acting injectable first generation antipsychotic; Brief
Psychiatric Rating Scale (BPRS) hallucinatory and unusual
thought content scores p5 and conceptual disorganization
score p4, Simpson Angus Scale score p6, and Calgary
Depression Rating Scale score p10; Wechsler Test of Adult
Reading score X6; capacity to provide written informed
consent. Exclusion criteria: treatment with clozapine,
diagnosis of alcohol or substance abuse within the last
month or alcohol or substance dependence within the last
6 months; history of significant head injury/trauma or
significant medical or neurological disease. For the MRS
protocol, participants were also excluded for claustropho-
bia, left handedness and metallic implants or paramagnetic
objects in their bodies.
Study Design and Assessments
Eligible subjects entered a 2-week stabilization phase during
which baseline neuropsychological ratings (including
MCCB, UPSA), ratings of psychopathology, and safety
measures were obtained, see Javitt et al. (2012) for details.
Subjects who remained stable during the stabilization phase
were randomized to low-dose (5 mg) or high-dose (30 mg)
intranasal davunetide or placebo (saline solution). For the
low-dose group, one intranasal puff was administered daily;
for the high-dose group, three puffs were administered
twice daily. For the placebo group, half of the subjects were
assigned to the low-dose group and half were assigned to
Davunetide and brain metabolites in schizophrenia
LF Jarskog et al
1246
Neuropsychopharmacology
the high-dose group, with the number of placebo puffs
matching the low and high-dose davunetide groups,
respectively.
Subjects received study drug for 12 weeks. MCCB and UPSA
were performed at weeks 6 and 12. Ratings of psychopathol-
ogy and safety measures were obtained biweekly.
MRS Protocol
1H-MRS was performed on 3 T scanners at baseline and at
the end of 12 weeks of randomized treatment. An 8 cc MRS
voxel was placed in the DLPFC using a protocol developed
by Dr Dikoma Shungu (Weill Cornell Medical College, NY,
NY) by first acquiring a 3-plane localizer MRI series. Next, 3
oblique MRI localizer series were acquired: an axial/oblique
MRI series parallel to the Sylvian fissure, a coronal/oblique
localizer MRI series perpendicular to the previous axial/
oblique planes, and a sagittal/oblique MRI series. To ensure
correct slice prescription, the anterior commissure was
located on a coronal/oblique image and the sagittal/oblique
slices were oriented parallel to the brain surface at the
middle frontal gyrus, forming a B451 angle with the inter-
hemispheric fissure.
Following acquisition of the three series localizer images, an
8-cc voxel was deposited on the sagittal/oblique series, with
the longest direction along the antero-posterior axis (40 mm)
and the other two directions measuring 10 20 mm2. A
screenshot of the voxel placement was captured for each
subject for the quality assurance (QA) process.
Data Acquisition
Scanners at the MRS sites: Columbia—Signa 14 3.0 T (GE
Healthcare, Waukesha, WI); Duke—Signa EXCITE HD 3.0 T
(GE); Washington U.—Siemens Trio 3.0 T (Siemens AG,
Erlangen, Germany). The Harvard site did not yield usable
MRS baseline/week 12 scan-pairs. Pulse sequence for single
voxel MRS with PRESS localization was used for data
acquisition in all sites with the following parameters: TR/
TE¼ 1700/144 ms, spectral width¼ 2000 Hz, number of data
points¼ 2048; number of excitation¼ 256; voxel size¼ 8 cc.
Water signal was suppressed for metabolite scans. Outer
volume suppression bands were placed around the voxel.
Quality Assurance
All sites implemented the protocols using a standard
spectroscopic phantom and a human phantom that were
sent to each site. The phantom data were then sent to the
central site for ascertainment of the pulse sequence
parameters, the placement of the voxel and the quality of
the spectra (including signal-to-noise ratio (SNR), line-
width, and baseline) to determine inter-site comparability
and reliability.
QA scans were conducted at each site using spectroscopic
phantoms on a monthly basis throughout the data
acquisition period. Two measures were used to represent
test–retest reliability, one was the variation of NAA/Cr and
the other was the correlation of NAA and Cr. The former
was 2.16% and the latter was 0.94. Both showed high test–
retest reliability.
Data Processing
All data, including the screenshots for voxel placement,
were processed at the central site. Preprocessing procedures
entailed a combination of multichannel data, water residue
removal by a matrix-pencil-based procedure (Dong et al,
2006), and spectral filtering by a Gaussian function
corresponding to a 4-Hz linewidth. As an assessment of
the spectral quality, the overall SNRs (mean±SD) of all
valid scans were 99.56±19.38 (NAA), 56.82±15.73 (Cr),
and 50.05±18.43 (choline). Spectral fitting was performed
in the spectral domain with an algorithm that fitted the
spectrum with several individual lines with Voigtian line-
shape. Restrictions on the linewidths and frequencies were
imposed according to a priori knowledge to improve the
accuracy of the fitting. The Cramer Rao lower bounds for all
fittings of NAA, Cr and Ch were below 20%. Areas of NAA,
choline and Cr were measured based on the fitted spectral
lines. All data were processed in a blinded manner.
Statistical Analyses
In order to measure the longitudinal effect of treatment,
only MRS data for subjects who successfully completed both
a baseline and a week 12 scan were included in the analyses.
Analyses of change in NAA/Cr and choline/Cr in davunetide
compared with placebo groups were performed using exact
(permutation) P-values from pairwise Wilcoxon rank sum
tests. This test was used given that the neurochemical
metabolite data in this small sample could not be assumed
to have a normal distribution. Spearman correlations were
used to perform correlation analyses between metabolites
and cognitive testing scores. Spearman partial correlations
were also performed between end-of-study metabolites and
cognitive scores, adjusting for differences in baseline
metabolites and cognitive scores. Given that this was an
exploratory, hypothesis-generating sub-study, outcomes
were not corrected for multiple comparisons. Descriptive
statistics are presented as mean±SD. All statistical analyses
were performed using SAS version 9.2.3 (SAS, Cary, NC).
RESULTS
Baseline Characteristics
Nineteen subjects completed MRS scans at baseline and week
12 (11 subjects at Washington USA, 5 subjects at Columbia,
2 subjects at Duke and 1 subject at Harvard). MRS data for
one subject was not usable owing to technical problems
(Harvard). Of the remaining 18 subjects, 11 (age: 41.7±9.8
years) received davunetide (8 high dose (30 mg/day), 4
female/4 male; 3 low dose (5 mg/day), 1 female/2 male) and 7
subjects (age: 38.0±9.4, 5 female/2 male) received placebo.
NAA/Cr
Change in NAA/Cr with davunetide (high- and low-dose
groups combined) was not significantly different compared to
placebo (P¼ 0.104), see Table 1 and Figure 1a. Analyzing
dosing groups separately, davunetide 30 mg/day showed a
trend increase in NAA/Cr ratio (8.0%; P¼ 0.072) compared
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with placebo, while davunetide 5 mg/day showed no change
(P¼ 0.667).
Choline/Cr. Davunetide treatment (high- and low-dose
groups combined) showed a trend increase in choline/Cr
compared with placebo (6.4%; P¼ 0.069), see Table 1 and
Figure 1b. Analyzed separately, davunetide 30 mg/day was
associated with a 7.9% increase in choline/Cr compared
with placebo (P¼ 0.040), while davunetide 5 mg/day showed
no change (P¼ 0.667).
Correlation between NAA/Cr, choline/Cr and Cognitive
Performance
The overall MCCB composite T-score correlated with NAA/
Cr at baseline (R¼ 0.52, P¼ 0.033), as did individual
domains of attention/vigilance (R¼ 0.69, P¼ 0.002), verbal
learning (R¼ 0.64, P¼ 0.004) and social cognition (R¼ 0.48,
P¼ 0.042), see Table 2. In contrast, baseline MCCB
measures did not correlate with choline/Cr ratios. The
baseline UPSA summary score did not correlate with NAA/
Cr (R¼ 0.38, P¼ 0.118) or choline/Cr (R¼ 0.15, P¼ 0.556).
Correlations of change between NAA/Cr and MCCB
T-scores over 12 weeks were analyzed in davunetide-treated
participants. Neither change in MCCB composite T-score
nor individual MCCB domain scores correlated with change
in NAA/Cr. Partial correlations between end-of-study NAA/
Cr and MCCB T-scores, adjusted for baseline NAA/Cr and
MCCB T-scores, were also determined for davunetide-
treated patients. A significant negative partial correlation
emerged between NAA/Cr and the MCCB working memory
battery and the WMS III Spatial Span test, see Table 3.
Similar analyses of correlation of change between choline/
Cr and MCCB T-scores and partial correlation analyses
showed no relationship in davunetide-treated patients
(data not shown).
In davunetide-treated patients, change in UPSA summary
score and change in NAA/Cr showed no correlation
(R¼  0.26, P¼ 0.43). Similarly, change in UPSA summary
score and change in choline/Cr were not correlated
(R¼  0.25, P¼ 0.45).
DISCUSSION
1H-MRS was used to measure neurochemical metabolites in
DLPFC before and after 12 weeks of davunetide treatment in
clinically stable patients with schizophrenia. The study
suggested a modest increase in both NAA/Cr and choline/Cr
with high-dose davunetide compared with placebo, although
the change in NAA/Cr remained a statistical trend. Although
the exact biological function of NAA remains unclear, low
NAA/Cr has been identified as a marker of impaired
neuronal function in neuropathological disorders ranging
from schizophrenia to Alzheimer’s disease (Moffett et al,
2007). The current results showing davunetide-associated
increase in NAA/Cr and choline/Cr provides preliminary
evidence that davunetide can exert beneficial effects in a
brain region previously found to have low NAA/Cr, reduced
synaptic content and dendritic atrophy in people with
schizophrenia (Glantz and Lewis, 1997, 2000).
Earlier studies in people with schizophrenia have demon-
strated correlations between reduced NAA and deficits in
cognitive performance, including verbal learning (Ohrmann
et al, 2007) and working memory (Bertolino et al, 2003;
Callicott et al, 2000). Baseline cognitive performance in this
study was consistent with prior studies showing a correla-
tion between NAA/Cr and cognitive performance. To our
knowledge, this represents the first use of the MCCB in
conjunction with MRS assessment. The MCCB is a
frequently applied cognitive testing battery for people with
schizophrenia, and the current data support NAA/Cr as a
useful biomarker for cognitive dysfunction together with
the MCCB.
Although cognitive function correlated with NAA/Cr at
baseline, change in NAA/Cr or choline/Cr did not correlate
with change in cognitive performance. Furthermore,
although the parent trial showed modest functional im-
provement based on the UPSA score for davunetide 5 mg/
day, the UPSA score did not correlate with NAA/Cr or
choline/Cr for either the lower or higher davunetide doses.
Given the limited statistical power in this exploratory study,
the overall lack of correlation between change in neuro-
chemical metabolites and change in cognitive function or
change in functional capacity may not be surprising and larger
cohorts are needed to test whether such relationships exist.
Furthermore, the duration of treatment that may be
required for cognitive enhancement is uncertain. To
activate neurotrophic mechanisms and for new or rein-
forced synaptic connectivity to translate into clinically
measurable effects may require considerably longer ex-
posure than 12 weeks in people with schizophrenia.
Evidence from the current study of modestly higher NAA/
Cr and choline/Cr may reflect activation of neurotrophic
mechanisms, but that such effects may only have started to
affect synaptic connectivity and broader circuit function.
It is possible that davunetide and comparable neurotrophic
agents may require considerably longer exposures (possibly
Table 1 NAA/Cr and Choline/Cr at Baseline and Week 12
Arm Baseline Week 12 Week 12—BL P
N mean SD N Mean SD Mean SD
NAA/Cr
DAVa 11 1.66 0.26 11 1.77 0.30 0.11 0.12 0.104
PBO 7 1.92 0.19 7 1.92 0.13  0.0 0.11
DAV 30 mg 8 1.63 0.29 8 1.75 0.36 0.13 0.13 0.072
DAV 5 mg 3 1.77 0.08 3 1.82 0.05 0.05 0.11 0.667
Choline/Cr
DAVa 11 0.842 0.145 11 0.896 0.165 0.054 0.071 0.069
PBO 7 0.868 0.058 7 0.869 0.075 0.0 0.080
DAV 30 mg 8 0.831 0.158 8 0.897 0.194 0.066 0.066 0.040
DAV 5 mg 3 0.872 0.126 3 0.893 0.077 0.021 0.050 0.667
Abbreviations: BL, baseline; Cr, creatine; DAV, davunetide; NAA,
N-acetylaspartate; PBO, placebo.
P¼ Exact Wilcoxon test P value for differences in neurochemical metabolites for
davunetide compared with placebo.
aDAV 5 and 30 mg doses combined.
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up to 1 year or longer) to demonstrate robust functional
improvements in people with schizophrenia.
Davunetide is an eight-amino acid chain peptide con-
tained within ADNP. ADNP is an essential protein
for normal brain development (Pinhasov et al, 2003).
Preclinical studies have demonstrated that davunetide can
promote neurite outgrowth and synaptogenesis (Smith-
Swintosky et al, 2005). Animal studies suggest a potential
therapeutic role for davunetide through its ability to
stabilize microtubules and rescue cognitive deficits in
several models of neurodegeneration (Merenlender-
Wagner et al, 2010; Vulih-Shultzman et al, 2007). Although
speculative, the evidence for a modest davunetide-
associated increase in NAA/Cr in the high-dose group
is consistent with a neurotrophic mechanism of action.
A similar argument can be made for the small but
significant increase in choline/Cr in the high-dose davune-
tide group. Choline is often considered a marker of
membrane phospholipid turnover. In Alzheimer’s disease,
studies consistently find elevated choline/Cr together with
low NAA/Cr, which is thought to reflect active membrane
phospholipid breakdown associated with neuronal cell loss
(Soher et al, 2005). Similarly, reports indicate that choline/
Cr is elevated and NAA/Cr is reduced during multiple
sclerosis lesion exacerbation, likely reflecting active demye-
lination/remyelination (Sajja et al, 2009). In classic neuro-
degenerative disorders, elevated choline/Cr and low NAA/
Cr co-occur during clinical worsening. This is in contrast to
the current study where both markers increase in tandem
following davunetide treatment, together with at least some
evidence for functional improvement. As the pathophysiol-
ogy of schizophrenia is not thought to be associated with
neuronal cell loss or demyelination, nor was there any
evidence of physical or psychiatric deterioration associated
with davunetide treatment in the current study, a plausible
interpretation of the modest parallel increase in choline/Cr
and NAA/Cr is that these represent davunetide-mediated
neurotrophic/neuroprotective effects. Further insight into
this issue may be gained preclinically by probing a
davunetide-treated animal model with high-field MRS and
postmortem quantitative histochemistry.
The current study has several limitations. First, the
sample size was small and statistical power was therefore
limited to demonstrating changes with large effect sizes.
Second, the treatment duration may have been too short to
demonstrate a measurable response in cognitive and
functional outcomes from a drug that may require longer
brain exposure to produce structural neuronal changes.
Third, the voxel placed in the DLPFC encompassed both
gray and white matter and the relative contributions from
each compartment could not be assessed. Assessing changes
in brain metabolites in gray and white matter separately
would represent an important focus for future studies.
Fourth, antipsychotic treatment was not standardized
for enrolled subjects. Several studies have suggested that
antipsychotic treatment or withdrawal of treatment may

























































Figure 1 Before-and-after plot of N-acetylaspartate/creatine (NAA/Cr) and choline/creatine (choline/Cr) across all subjects. (a) Baseline (BL) and week
12 NAA/Cr values for each subject who received placebo (PBO) and davunetide (DAV). Closed squares represent high-dose DAV and open squares
represent low-dose DAV. (b) BL and week 12 choline/Cr values for each subject who received PBO and DAV. Closed triangles represent high-dose DAV
and open triangles represent low-dose DAV.
Table 2 Spearman Correlations between NAA/Cr and Cognitive/
Functional Domains at Baseline
N R P
MCCB
Attention/vigilance 17 0.69 0.002
Processing speed 18 0.30 0.223
Trails A 18 0.03 0.919
BACS symbol coding 18 0.45 0.062
Fluency 18 0.26 0.302
Reasoning/problem solving 18 0.35 0.156
Social cognition 18 0.48 0.042
Verbal learning 18 0.64 0.004
Visual learning 18 0.24 0.335
Working memory 18 0.24 0.348
WMS III spatial span 18 0.14 0.580
Letter number sequencing 18 0.37 0.131
MCCB composite T-score 17 0.52 0.033
UPSA summary score 18 0.38 0.118
Abbreviations: BACS, Brief Assessment of Cognition in Schizophrenia;
Cr, creatine; MCCB, MATRICS consensus cognitive battery; NAA,
N-acetylaspartate; UPSA, UCSD Performance-based Skills Assessment; WMS III,
Wechsler Memory Scale, 3rd edition.
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et al, 2001; Ertugrul et al, 2009). To limit potential
antipsychotic treatment confounds, only patients taking
stable antipsychotic drug regimens were enrolled.
Furthermore, a 6-month longitudinal MRS study in haloper-
idol-treated rats found no effect of antipsychotic treatment
on NAA or choline in cortical brain regions (Bustillo
et al, 2006).
In summary, 12 weeks of davunetide was associated with
a modest increase in choline/Cr and a suggestive increase in
NAA/Cr in DLPFC in clinically stable people with schizo-
phrenia taking antipsychotic medication. These data
provide preliminary evidence that davunetide can exert
neurotrophic effects in people with schizophrenia in a brain
region with known dendritic and synaptic deficits. The
study also supports prior reports that NAA represents a
useful biomarker of baseline cognitive function in this
population. Future studies with larger sample sizes and
longer treatment exposure are needed to better establish the
potential benefits of davunetide in schizophrenia.
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T-scores, adjusted for baseline NAA/Cr and T-scores
N R P N R P
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Abbreviations: BACS, Brief Assessment of Cognition in Schizophrenia; Cr, creatine; MCCB, MATRICS consensus cognitive battery; NAA, N-acetylaspartate; WMS III,
Wechsler Memory Scale, 3rd edition.
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